GLP-1 Drugs Show Promise in Reducing Cancer Mortality
TL;DR Summary
A study from UC San Diego suggests that GLP-1 receptor agonists like Wegovy and Ozempic, originally for diabetes and weight loss, may significantly reduce mortality in colon cancer patients, especially those with obesity, but clinical trials are needed to confirm their direct anti-cancer effects.
- Wegovy and Ozempic tied to dramatically lower cancer deaths ScienceDaily
- GLP-1 Drugs Linked to Dramatically Lower Death Rates in Colon Cancer Patients UC San Diego Today
- UT Health Science Center’s Liza Makowski, PhD, Helps Lead Global Conversation on GLP-1 Drugs and Cancer Risk UTHSC News
- Colon cancer: Can GLP-1 drugs help in lowering death rates? The Times of India
- Can GLP-1 Drugs Protect Against Lung Cancer in T2D? Medscape
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
91%
464 → 44 words
Want the full story? Read the original article
Read on ScienceDaily